Awards & Advancement

Redwood secures funding for drug development

Monday, July 11, 2011 12:46 PM

Redwood Bioscience has secured funding from Takeda Ventures to further develop its precision protein-chemical engineering platform for drug conjugate optimization.  This funding will be applied to advancing Redwood's site specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.  

More... »

PROLOR receives allowance for patent application

Monday, July 11, 2011 12:43 PM

PROLOR Biotech has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company’s CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity protein ligands, proteins that induce or regulate an immune response, proteins that are involved with autocrine and paracrine activities and mimetics of these therapeutic proteins, as well as other types of proteins.

More... »

PPD names Ian vice president of clinical development

Monday, July 11, 2011 12:39 PM

PPD has appointed Edward Ian vice president of clinical development for Asia Pacific. Ian will be based in Singapore and will provide strategic leadership and operational oversight for PPD's phase II-IV business in the region.

More... »

MRIGlobal names Winegar principal advisor for science

Monday, July 11, 2011 12:37 PM

MRIGlobal, an international R&D organization has appointed Richard A. Winegar, Ph.D., principal advisor for science.

More... »

Cellectis names Dr. Scharenberg chief scientific officer

Monday, July 11, 2011 12:35 PM

Cellectis Therapeutics, a Cellectis subsidiary specializing in the development of therapeutic applications in genome engineering, has named Dr. Andrew M. Scharenberg chief scientific officer.

More... »

Zafgen receives $33 million in Series C financing

Friday, July 8, 2011 01:00 PM

Zafgen, a pharmaceutical company, announced the closing of a $33 million Series C financing led by the existing investor syndicate, including Atlas Venture and Third Rock Ventures. The financing will be used to support development of Zafgen's pipeline and to advance its lead methionine aminopeptidase 2 (MetAP2) inhibitor for the treatment of severe obesity into phase II clinical studies.

More... »

Northwest Biotherapeutics receives $4.55 million investment

Friday, July 8, 2011 12:54 PM

Northwest Biotherapeutics has announced a $4.55 million equity investment by The Richard M. Schulze Family Foundation.  The sale of newly issued common stock of the company to the foundation follows the investment of $3 million by investment funds managed by Whitebox Advisors. The foundation has been focused for a number of years on game-changing medical research and treatment breakthroughs.  

More... »

Lium to lead UCSF Innovation Office

Friday, July 8, 2011 12:51 PM

UCSF Assistant Vice Chancellor Erik Lium, Ph.D., has been chosen to lead the university’s newly created Office of Innovation, Technology and Alliances (ITA), effective immediately, according to UCSF News Center.

More... »

Integromics announces winners of grant competition

Friday, July 8, 2011 12:38 PM

Integromics has announced the two winners of the Integromics “Proteomics Mass Spectrometry Research Grant” competition for the creative use of Integromics' OmicsHub proteomics solution.

More... »

ERT names Kleiman Chief Medical Officer

Friday, July 8, 2011 12:36 PM

ERT, a global technology-driven provider of clinical services and customizable medical devices, has named Robert Kleiman Chief Medical Officer, in addition to his current role as Vice President of Global Cardiology. 

More... »